SG
AUTL

StoneX Group’s Autolus Therapeutics AUTL Stock Holding History

StoneX Group’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.3K Buy
+16,965
New +$26.6K ﹤0.01% 1283

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

StoneX Group's AUTL Position: Q2 2026 in Review

StoneX Group opened a new position in Autolus Therapeutics (AUTL) in Q2 2026: 16,965 shares worth $27.3K. The stake represents ﹤0.01% of the portfolio and ranks #1283 among its holdings.

84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • StoneX Group held 16,965 shares of Autolus Therapeutics worth $27.3K as of Q2 2026.
  • Autolus Therapeutics was a new StoneX Group position in Q2 2026.
  • Autolus Therapeutics made up ﹤0.01% of StoneX Group's portfolio in Q2 2026, its #1283 holding.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.